Cited by 1,463Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug ReactionsMuscle and Compartmental Disorders

The DOI matches its Crossref record; 103 of the 114 references it cites were found in a registry or an index.

Statin-Associated Myopathy

Thompson, Paul D., Clarkson, Priscilla, Karas, Richard H.·2003·JAMA

DOI 10.1001/jama.289.13.1681

Open this paper in CoChat — free account

Abstract

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevations, myalgia with and without elevated CK levels, muscle weakness, muscle cramps, and persistent myalgia and CK elevations after statin withdrawal. We performed a literature review to provide a clinical summary of statin-associated myopathy and discuss possible mediating mechanisms. We also update the US Food and Drug Administration (FDA) reports on statin-associated rhabdomyolysis. Articles on statin myopathy were identified via a PubMed search through November 2002 and articles on statin clinical trials, case series, and review articles were identified via a PubMed search through January 2003. Adverse event reports of statin-associated rhabdomyolysis were also collected from the FDA MEDWATCH database. The literature review found that reports of muscle problems during statin clinical trials are extremely rare. The FDA MEDWATCH Reporting System lists 3339 cases of statin-associated rhabdomyolysis reported between January 1, 1990, and March 31, 2002. Cerivastatin was the most commonly implicated statin. Few data are available regarding the frequency of less-serious events such as muscle pain and weakness, which may affect 1% to 5% of patients. The risk of rhabdomyolysis and other adverse effects with statin use can be exacerbated by several factors, including compromised hepatic and renal function, hypothyroidism, diabetes, and concomitant medications. Medications such as the fibrate gemfibrozil alter statin metabolism and increase statin plasma concentration. How statins injure skeletal muscle is not clear, although recent evidence suggests that statins reduce the production of small regulatory proteins that are important for myocyte maintenance.

Integrity signals

Registry

Crossref · 10.1001/jama.289.13.1681

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453

Show all 114 references

Research works printed but not linked: 9

Fuhrmans, 2002, Bayer discloses higher death toll from Baycol., Wall Street Journal, A10
Hamilton-Craig, 2001, Statin-associated myopathy., Med J Aust, 175, 486, 10.5694/mja2.2001.175.issue-9 · DOI
Omar, 2002, FDA adverse event reports on statin-associated rhabdomyolysis., Ann Pharmacother, 36, 288, 10.1345/aph.1A289 · DOI · Paper page
GISSI Prevenzione Investigators, 2000, Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)?, Ital Heart J, 1, 810
Omar, 2001, Rhabdomyolysis and HMG-CoA reductase inhibitors., Ann Pharmacother, 35, 1096, 10.1345/aph.10228 · DOI · Paper page
Shek, 2001, Statin-fibrate combination therapy., Ann Pharmacother, 35, 908, 10.1345/aph.10315 · DOI · Paper page
Prueksaritanont, 2002, Metabolic interactions between gemfibrozil and statins in human liver preparations [abstract]., Circulation, 106, II185
Not Available, 2001, Cardiovascular Trials Review
Not Available, 2002, Cardiovascular Trials Review

Sorted by citations

Items 401–500 of 1,001

Mechanisms of simvastatin myotoxicity: The role of autophagy flux inhibition
Emami, A., Shojaei, S., Rosa, S. C. D. S., Aghaei, M., Samiei, E., Vosoughi, A. R., Kalantari, F., Kawalec, P., Thliveris, J. A., Sharma, P. K., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172616 · Cited by 42
Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence
Camerino, G. M., Tarantino, N., Canfora, I., Bellis, M. D., Musumeci, O., & Pierno, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042070 · Cited by 47
Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin
Francis, L., Bonilla, E., Soforo, E., Neupane, H., Nakhla, H., Fuller, C. E., & Perl, A. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0696-9 · Cited by 42
The expanding phenotype of mitochondrial myopathy
DiMauro, S., & Gurgel‐Giannetti, J. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000179761.63486.1a · Cited by 42
Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study
Goettsch, W., Heintjes, E. M., Kastelein, J. J. P., Rabelink, T. J., Johansson, S., & Herings, R. M. C. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1278 · Cited by 42
The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease
Zhao, Y., Wu, T., Zhao, M., & Li, C. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.008897 · Cited by 42
Safety of statins: effects on muscle and the liver.
Vasudevan, A. R., Hamirani, Y. S., & Jones, P. H. (2005) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.72.11.990 · Cited by 42
Decreased Ubiquinone Availability and Impaired Mitochondrial Cytochrome Oxidase Activity Associated With Statin Treatment
Duncan, A. J., Hargreaves, I. P., Damian, M. S., Land, J. M., & Heales, S. (2008) · Toxicology Mechanisms and Methods · doi:10.1080/15376510802305047 · Cited by 41
Muscle toxicity with statins
Hedenmalm, K., Alván, G., Öhagen, P., & Dahl, M. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1895 · Cited by 41
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
Gilde, A. J., Fruchart, J., & Staels, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.097 · Cited by 42
Whole genome association studies in complex diseases: where do we stand?
Need, A. C., & Goldstein, D. B. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.1/aneed · Cited by 40
Lipid-induced Muscle Insulin Resistance Is Mediated by GGPPS via Modulation of the RhoA/Rho Kinase Signaling Pathway
Tao, W., Wu, J., Xie, B., Zhao, Y., Shen, N., Jiang, S., Wang, X., Xu, N., Chen, J., Chen, S., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657742 · Cited by 37
Statin Therapy and the Expression of Genes that Regulate Calcium Homeostasis and Membrane Repair in Skeletal Muscle
Draeger, A., Sánchez-Freire, V., Monastyrskaya, K., Hoppeler, H. H., Mueller, M., Breil, F., Mohaupt, M. G., & Babiychuk, E. B. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091140 · Cited by 40
Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy
Vishwanath, R. L., & Hemphill, L. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.11.002 · Cited by 40
Gene expression in skeletal muscle of coronary artery disease patients after concentric and eccentric endurance training
Zoll, J., Steiner, R., Meyer, K., Vogt, M., Hoppeler, H., & Flück, M. (2005) · European Journal of Applied Physiology · doi:10.1007/s00421-005-0082-8 · Cited by 40
Drug interactions with statins
Čaušević-Ramoševac, A., & Semiz, S. (2013) · Acta Pharmaceutica · doi:10.2478/acph-2013-0022 · Cited by 41
Attenuation of osteoarthritis progression in mice following intra‐articular administration of simvastatin‐conjugated gelatin hydrogel
Tanaka, T., Matsushita, T., Nishida, K. K., Takayama, K., Nagai, K., Araki, D., Matsumoto, T., Tabata, Y., & Kuroda, R. (2019) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2804 · Cited by 40
Mitochondrial dysfunction and role of harakiri in the pathogenesis of myositis
Boehler, J., Horn, A. J., Novak, J. S., Li, N., Ghimbovschi, S. D., Lundberg, I. E., Alexanderson, H., Munters, L. A., Jaiswal, J. K., & Nagaraju, K. (2019) · The Journal of Pathology · doi:10.1002/path.5309 · Cited by 40
ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis
Su, J., Xu, J., Yang, J., Yu, Q., Yang, S., Zhang, J., Yao, Q. Z., Zhu, Y., Luo, Y., Ji, L., et al. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0114-2 · Cited by 40
Oral Nanoparticulate Atorvastatin Calcium is More Efficient and Safe in Comparison to Lipicure® in Treating Hyperlipidemia
Meena, A. K., Ratnam, D. V., Chandraiah, G., Ankola, D. D., Rao, P. R., & Kumar, M. N. V. R. (2008) · Lipids · doi:10.1007/s11745-007-3142-5 · Cited by 40
Pitavastatin, an HMG-CoA Reductase Inhibitor, Ameliorates Endothelial Function in Chronic Smokers
Yoshida, O., Kondo, T., Kureishi-Bando, Y., Sugiura, T., Maeda, K., Okumura, K., & Murohara, T. (2009) · Circulation Journal · doi:10.1253/circj.cj-09-0345 · Cited by 40
Pharmacological activation of the pyruvate dehydrogenase complex reduces statin‐mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents
Mallinson, J. E., Constantin‐Teodosiu, D., Glaves, P. D., Martin, E. A., Davies, W. J., Westwood, F. R., Sidaway, J. E., & Greenhaff, P. L. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2012.238022 · Cited by 40
Modulation of Systemic Metabolism by MMP‐2: From MMP‐2 Deficiency in Mice to MMP‐2 Deficiency in Patients
Fernández-Patrón, C., Kassiri, Z., & Leung, D. (2016) · Comprehensive physiology · doi:10.1002/cphy.c160010 · Cited by 40
Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.
Marot, A., Morelle, J., Chouinard, V., Jadoul, M. Y., Lambert, M. J., & Demoulin, N. (2011) · PubMed · doi:10.2143/acb.66.2.20625533 · Cited by 39
A simple assay for the simultaneous determination of rosuvastatin acid, rosuvastatin-5S-lactone, and N-desmethyl rosuvastatin in human plasma using liquid chromatography–tandem mass spectrometry (LC-MS/MS)
Macwan, J. S., Ionita, I. A., & Akhlaghi, F. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-5548-4 · Cited by 39
Genetic and immunologic susceptibility to statin-related myopathy
Patel, J., Superko, H. R., Martin, S. S., Blumenthal, R. S., & Christopher‐Stine, L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.025 · Cited by 38
Genetics of Dyslipidemia
García-Giustiniani, D. A., & Stein, R. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160074 · Cited by 39
Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
Khoshnejad, M., Patel, A. R., Wojtak, K., Kudchodkar, S. B., Humeau, L. M. P. F., Lyssenko, N. N., Rader, D. J., Muthumani, K., & Weiner, D. B. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.016 · Cited by 39
Statin‐dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content
Christie, C. F., Fang, D., Hunt, E. G., Morris, M. E., Rovini, A. M. F., Heslop, K. A., Beeson, G. C., Beeson, C. C., & Maldonado, E. N. (2019) · The FASEB Journal · doi:10.1096/fj.201802723r · Cited by 39
Cardiovascular risk in stage 4 and 5 nephropathy
Yeo, F. E., Villines, T. C., Bucci, J. R., Taylor, A. J., & Abbott, K. C. (2004) · Advances in Chronic Kidney Disease · doi:10.1053/j.arrt.2004.01.010 · Cited by 39
Statin-induced rhabdomyolysis
Schreiber, D. H., & Anderson, T. R. (2006) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2005.08.020 · Cited by 39
Other therapy options and future strategies for treating patients with multiple sclerosis
Rizvi, S., & Bashir, K. (2004) · Neurology · doi:10.1212/wnl.63.12_suppl_6.s47 · Cited by 39
Off‐target effects of statins: molecular mechanisms, side effects and the emerging role of kinases
Lagunas‐Rangel, F. A., Liepinsh, E., Fredriksson, R., Alsehli, A. M., Williams, M. J., Dambrova, M., Jönsson, J., & Schiöth, H. B. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17309 · Cited by 42
In vivo 1D and 2D correlation MR spectroscopy of the soleus muscle at 7T
Ramadan, S. A., Ratai, E., Wald, L. L., & Mountford, C. E. (2010) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2010.02.008 · Cited by 38
Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management
Wen, Z., Yu, L., Hao, Y., Delavan, B., Huang, R., Mikailov, M., Tong, W., Li, M., & Liu, Z. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.06.006 · Cited by 38
Novel pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase inhibitors
Watanabe, T., Umezawa, Y., Takahashi, Y., & Akamatsu, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.131 · Cited by 37
Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver
Okazaki, H., Tazoe, F., Okazaki, S., Iso-O, N., Tsukamoto, K., Sekiya, M., Yahagi, N., Iizuka, Y., Ohashi, K., Kitamine, T., et al. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600224-jlr200 · Cited by 38
Post-Translational Regulation of HMG CoA ReductasePreprint
Jo, Y., & DeBose‐Boyd, R. A. (2022) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041253 · Cited by 38
Alterations in zebrafish development induced by simvastatin: Comprehensive morphological and physiological study, focusing on muscle
Campos, L. M., Rios, E. A., Guapyassu, L., Midlej, V. D. V. P., Atella, G. C., Herculano‐Houzel, S., Benchimol, M., Mermelstein, C., & Costa, M. L. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216659944 · Cited by 37
Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling
Li, S., Yu, Y., Jin, Z., Dai, Y., Lin, H., Jiao, Z., Ma, G., Cai, W., Han, B., & Xiang, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109416 · Cited by 39
Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes
Barbier, O., Fontaine, C., Fruchart, J., & Staels, B. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.07.007 · Cited by 37
A Randomized Clinical Trial to Assess the Effect of Statins on Skeletal Muscle Function and Performance: Rationale and Study Design
Thompson, P. D., Parker, B. A., Clarkson, P. M., Pescatello, L. S., White, C. M., Grimaldi, A. S., Levine, B. D., Haller, R. G., & Hoffman, E. P. (2010) · Preventive Cardiology · doi:10.1111/j.1751-7141.2009.00063.x · Cited by 37
Self-citation
Exploration of the Association Rules Mining Technique for the Signal Detection of Adverse Drug Events in Spontaneous Reporting Systems
Wang, C., Guo, X., Xu, J., Wu, C., Sun, Y., Ye, X., Qian, W., Ma, X., Du, W., & He, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040561 · Cited by 36
Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle
Camerino, G. M., Pellegrino, M. A., Brocca, L., Digennaro, C., Camerino, D. C., Pierno, S., & Bottinelli, R. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.022 · Cited by 37
CoQ10 and Resveratrol Effects to Ameliorate Aged-Related Mitochondrial Dysfunctions
Gherardi, G., Corbioli, G., Ruzza, F., & Rizzuto, R. (2022) · Nutrients · doi:10.3390/nu14204326 · Cited by 41
Physiologically based pharmacokinetic modeling of disposition and drug–drug interactions for atorvastatin and its metabolites
Zhang, T. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.06.019 · Cited by 37
Rhabdomyolysis secondary to influenza A H1N1 vaccine resulting in acute kidney injury
Callado, R. B., Carneiro, T. G. P., Parahyba, C. C. D. C., Lima, N. D. A., da Silva, G. B., & Daher, E. D. F. (2012) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2012.11.004 · Cited by 36
Sesquiterpenoids from Atractylodes macrocephala act as farnesoid X receptor and progesterone receptor modulators
Tsai, C.-J., Liang, J., & Lin, H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.048 · Cited by 36
Selected statins produce rapid spinal motor neuron loss in vitro
Murinson, B. B., Haughey, N. J., & Maragakis, N. J. (2012) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-13-100 · Cited by 36
The controversy of a wider statin utilization: why?
Mansi, I. A., & Mortensen, E. M. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.779667 · Cited by 37
Imaging Features of Therapeutic Drug–induced Musculoskeletal Abnormalities
Sidhu, H. S., Venkatanarasimha, N. K., Bhatnagar, G., Vardhanabhuti, V., Fox, B. M., & Suresh, S. P. (2012) · Radiographics · doi:10.1148/rg.321115041 · Cited by 36
Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin
Lehtisalo, M., Keskitalo, J. E., Tornio, A., Lapatto‐Reiniluoto, O., Deng, F. Y., Jaatinen, T., Viinamäki, J., Neuvonen, M., Backman, J. T., & Niemi, M. (2020) · Clinical and Translational Science · doi:10.1111/cts.12809 · Cited by 36
Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins
Filppula, A. M., Hirvensalo, P., Parviainen, H., Ivaska, V. E., Lönnberg, K. I., Deng, F. Y., Viinamäki, J., Kurkela, M. J., Neuvonen, M., & Niemi, M. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000406 · Cited by 38
Dermatomyosite induite par la pravastatine
Zuech, P., Pauwels, C., Duthoit, C., Mery‐Bossard, L., Somogyi, A., Louboutin, A., & Veyssier-Belot, C. (2005) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2005.07.005 · Cited by 36
(3 R, 5 S,E )-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1 H -1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic Acid (BMS-644950): A Rationally Designed Orally Efficacious 3-Hydroxy-3-methylglutaryl Coenzyme-A Reductase Inhibitor with Reduced Myotoxicity Potential
Ahmad, S., Madsen, C. S., Stein, P. D., Janovitz, E. B., Huang, C., Ngu, K., Bisaha, S. N., Kennedy, L. J., Chen, B., Zhao, R., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800001n · Cited by 36
Whole body vibration training elevates creatine kinase levels in sedentary subjects
Gojanovic, B., Liaudet, L., & Gremion, G. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13222 · Cited by 35
Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?
Agouridis, A. P., Rizos, C. V., Elisaf, M., & Filippatos, T. D. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.171 · Cited by 36
Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants
Kitzmiller, J. P. (2014) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000128 · Cited by 35
Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment
van Staa, T. P., Carr, D. F., O’Meara, H., McCann, G., & Pirmohamed, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12367 · Cited by 35
Enantiospecific Pharmacogenomics of Fluvastatin
Hirvensalo, P., Tornio, A., Neuvonen, M., Kiander, W., Kidron, H., Paile‐Hyvärinen, M., Tapaninen, T., Backman, J. T., & Niemi, M. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1463 · Cited by 35
Neuromuscular Complications of Statin Therapy
Crisan, E., & Patil, V. K. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01064-0 · Cited by 36
Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study
Abo-Zalam, H. B., El-Denshary, E. S., Abdelsalam, R. M., Khalil, I. A. H., Khattab, M. M., & Hamzawy, M. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111494 · Cited by 35
Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition II: Characterization of Hepatic Elimination by Basolateral, Biliary, and Metabolic Clearance Pathways in Rat Isolated Perfused Liver
Pfeifer, N. D., Bridges, A. S., Ferslew, B. C., Hardwick, R. N., & Brouwer, K. L. R. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208314 · Cited by 35
Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice
Kivist, K. T., Zukunft, J., Hofmann, U., Niemi, M., Rekersbrink, S., Schneider, S., Luippold, G., Schwab, M. G., Eichelbaum, M. F., & Fromm, M. F. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-0948-z · Cited by 35
Serum creatine kinase levels in chronic psychosis patients − a comparison between atypical and conventional antipsychotics
Melkersson, K. I. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.04.025 · Cited by 36
Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes.
Enas, E. A., Kuruvila, A. T., Khanna, P., Pitchumoni, C. S., & Mohan, V. (2013) · Europe PMC (PubMed Central) · Cited by 34
Neuroprotective effect of Lovastatin on motor deficit induced by sciatic nerve crush in the rat
Ghayour, M. B., Abdolmaleki, A., & Rassouli, M. B. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.018 · Cited by 34
Pathophysiological mechanisms of statin‐associated myopathies: possible role of the ubiquitin‐proteasome system
Sahebkar, A., Cicero, A. F. G., Giosia, P. D., Pomilio, I., Stamerra, C. A., Giorgini, P., Ferri, C., von Haehling, S., Banach, M., & Jamialahmadi, T. (2020) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12579 · Cited by 33
Effect of Cytochrome P450 3A5 Genotype on Atorvastatin Pharmacokinetics and Its Interaction with Clarithromycin
Shin, J., Pauly, D. F., Pacanowski, M. A., Langaee, T. Y., Frye, R. F., & Johnson, J. A. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.10.942 · Cited by 34
Asymptomatic hypothyroidism and statin-induced myopathy.
Bar, S. L., Holmes, D. T., & Frohlich, J. J. (2007) · Europe PMC (PubMed Central) · Cited by 34
Statins in Acute Coronary Syndromes
Morrissey, R. P., Diamond, G. A., & Kaul, S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.093 · Cited by 35
Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses
Briel, M., Nordmann, A. J., & Bucher, H. C. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.mol.0000191502.39831.ba · Cited by 34
The guinea pig as a preclinical model for demonstrating the efficacy and safety of statins
Madsen, C. S., Janovitz, E., Zhang, R., Nguyen-Tran, V., Ryan, C. S., Yin, X., Monshizadegan, H., Chang, M., D’Arienzo, C., Scheer, S., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131615 · Cited by 33
A randomized trial of coenzyme Q10 in patients with statin myopathy: Rationale and study design
Parker, B. A., Gregory, S. M., Lorson, L., Polk, D. M., White, C. M., & Thompson, P. D. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.02.002 · Cited by 33
Self-citation
Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia
Liu, D., Xu, L., Dong, H., Chen, G., Huang, Z., Zou, X. G., Wang, K., Luo, Y.-H., & Lu, F. (2014) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-014-1775-1 · Cited by 34
Relationships between HMG‐CoA reductase inhibitors (statin) use and strength, balance and falls in older people
Haerer, W., Delbaere, K., Bartlett, H., Lord, S. R., & Rowland, J. T. J. (2011) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02622.x · Cited by 33
SPONTANEOUS DISTAL BICEPS TENDON RUPTURES: ARE THEY RELATED TO STATIN ADMINISTRATION?
Savvidou, C., & Moreno, R. (2012) · Hand Surgery · doi:10.1142/s0218810412500153 · Cited by 33
Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle
Glueck, C. J., Abuchaibe, C., & Wang, P. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.07.007 · Cited by 34
Molecular modeling studies of atorvastatin analogues as HMGR inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations
Wang, Z., Cheng, L., Kai, Z., Wu, F., Liu, Z., & Cai, M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.055 · Cited by 34
Is the Yellow Knight Mushroom Edible or Not? A Systematic Review and Critical Viewpoints on the Toxicity of Tricholoma equestre
Rzymski, P., & Klimaszyk, P. (2018) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12374 · Cited by 33
Tissue-Engineered Human Myobundle System as a Platform for Evaluation of Skeletal Muscle Injury Biomarkers
Khodabukus, A., Kaza, A., Wang, J., Prabhu, N. K., Goldstein, R., Vaidya, V. S., & Bursac, N. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa049 · Cited by 34
Dermatomyosite induite par la fluvastatine
Thual, N., Penven, K., Chevallier, J.-M., Dompmartin, A., & Leroy, D. (2005) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(05)79565-x · Cited by 33
Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK
Collins, P. G. S., & Altman, D. G. (2012) · Heart · doi:10.1136/heartjnl-2012-302014 · Cited by 33
Drug-induced mitochondrial dysfunction in cardiac and skeletal muscle injury
Sardão, V. A., Pereira, S. L., & Oliveira, P. J. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.2.129 · Cited by 34
Rhabdomyolysis, myoglobinuria, and necrotizing myopathies
Shelton, G. D. (2004) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2004.05.020 · Cited by 33
Statin Use and the Risk of Type 2 Diabetes Mellitus in Children and Adolescents
Joyce, N. R., Zachariah, J. P. V., Eaton, C. B., Trivedi, A. N., & Wellenius, G. A. (2017) · Academic Pediatrics · doi:10.1016/j.acap.2017.02.006 · Cited by 33
Statin Treatment in Diabetes Mellitus
Buse, J. (2003) · Clinical Diabetes · doi:10.2337/diaclin.21.4.168 · Cited by 36
Perivascular sustained release of atorvastatin from a hydrogel-microparticle delivery system decreases intimal hyperplasia
Mylonaki, I., Strano, F., Déglise, S., Allémann, É., Alonso, F., Corpataux, J.-M., Deslarzes-Dubuis, C., Haefliger, J., Jordan, O., Saucy, F., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.023 · Cited by 32
Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta‐Analysis
Lin, Y., Lai, T., Wu, H., Chou, Y., Chiang, W., Lin, S., Chen, Y., Chu, T., & Tu, Y. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1859 · Cited by 32
Rhabdomyolysis Induced by Simvastatin-Fluconazole Combination
Hazin, R., Abuzetun, J. Y., Suker, M., & Porter, J. (2008) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)31280-3 · Cited by 32
Effects of Piperine, Cinnamic Acid and Gallic Acid on Rosuvastatin Pharmacokinetics in Rats
Basu, S., Jana, S., Patel, V. B., & Patel, H. (2012) · Phytotherapy Research · doi:10.1002/ptr.4894 · Cited by 32
Muscle Symptoms Associated with Statins: A Series of Twenty Patients
Soininen, K., Niemi, M., Kilkki, E., Strandberg, T. E., & Kivist, K. T. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_193.x · Cited by 32
A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs
Alla, V. M., Agrawal, V., DeNazareth, A., Mohiuddin, S., Ravilla, S., & Rendell, M. (2013) · Drugs · doi:10.1007/s40265-013-0072-9 · Cited by 33
Rhabdomyolysis due to the additive effect of statin therapy and hypothyroidism: a case report
Yeter, E., Keleş, T., Durmaz, T., & Bozkurt, E. (2007) · Journal of Medical Case Reports · doi:10.1186/1752-1947-1-130 · Cited by 32
The Effects of Statin Medications on Aerobic Exercise Capacity and Training Adaptations
Murlasits, Z., & Radak, Z. O. (2014) · Sports Medicine · doi:10.1007/s40279-014-0224-4 · Cited by 32
Physician Utilization, Risk-Factor Control, and CKD Progression Among Participants in the Kidney Early Evaluation Program (KEEP)
Jurkovitz, C. T., Elliott, D. J., Li, S., Saab, G., Bomback, A. S., Norris, K. C., Chen, S., McCullough, P. A., & Whaley‐Connell, A. T. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.11.019 · Cited by 31
In silico prediction of drug‐induced rhabdomyolysis with machine‐learning models and structural alerts
Cui, X., Liu, J., Zhang, J., Wu, Q., & Li, X. (2019) · Journal of Applied Toxicology · doi:10.1002/jat.3808 · Cited by 33
Potential statin drug interactions in elderly patients: a review
Damiani, I., Corsini, A., & Bellosta, S. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1822324 · Cited by 31
Berberine Reduces Neurotoxicity Related to Nonalcoholic Steatohepatitis in Rats
Ghareeb, D. A., Khalil, S., Hafez, H. S., Bajorath, J., Ahmed, H. E. A., Sarhan, E., Elwakeel, E., & Demellawy, M. E. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/361847 · Cited by 31
Myotoxicity of Lipid-Lowering Agents in a Teenager With MELAS Mutation
Tay, S. K. H., DiMauro, S., Pang, A., Lai, P. S., & Yap, H. (2008) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2008.09.002 · Cited by 31

Authors: Thompson, P. D., Clarkson, P., & Karas, R. H.
Affiliations: Hartford Hospital (US)
ORCID: Thompson, Paul D.
Karas, Richard H.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2003-04-02
Volume: 289
Issue: 13
Pages: 1681
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.289.13.1681
OpenAlex: W2059078444
Cited by: 1,463
References: 114
Citations by year: 2026: 8 · 2025: 22 · 2024: 31 · 2023: 27 · 2022: 30 · 2021: 33 · 2020: 38 · 2019: 54 · 2018: 52 · 2017: 54 · 2016: 79 · 2015: 60 · 2014: 76 · 2013: 75 · 2012: 97
FWCI: 19.53
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
ScholarWorks@UMassAmherst (University of Massachusetts Amherst) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
Keywords: statin-induced myopathy, statins, rhabdomyolysis, myositis, creatine kinase elevation, myalgia, statin withdrawal, adverse drug reactions, cerivastatin, gemfibrozil, drug interactions
MeSH terms: Anticholesteremic Agents, Creatine Kinase, Humans, Muscle Cramp, Muscular Diseases, Myositis, Rhabdomyolysis, Adverse Drug Reaction Reporting Systems, Muscle, Skeletal, Muscle Weakness, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Statin-Associated Myopathy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks